跳至主要内容
临床试验/EUCTR2015-004986-99-IT
EUCTR2015-004986-99-IT进行中(未招募)1 期

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Investigating the Optimal Dose Regimen, Efficacy, and Safety of Adding Oral Cysteamine in Adult Patients with Cystic Fibrosis (CF) Being Treated for an Exacerbation of CF-associated Lung Disease.

ovaBiotics, Ltd0 个研究点目标入组 120 人开始时间: 2016年9月6日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. CF-associated lung disease with documented history of chronic infection with Gram-negative organism(s)
  • 2. Established patient of the Principal Investigator's CF Multi-Disciplinary team
  • 3. Age equal or greater than 18 years
  • 4. Weight equal or more than 40 Kg
  • 5. FEV1 more than 30% of predicted within the 6 months prior to study exacerbation
  • 6. At baseline visit: experiencing a new exacerbation of CF associated lung disease requiring treatment that includes an aminoglycoside antibiotic
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 120
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range 0

排除标准

  • 1. Hypersensitive to cysteamine or to any of the excipients
  • 2. Hypersensitive to penicillamine
  • 3. Transplant recipient

研究者

发起方
ovaBiotics, Ltd

相似试验